Proteins From Micro-organisms Patents (Class 530/820)
  • Patent number: 9017699
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 28, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 8906360
    Abstract: The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: December 9, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Edward S. Boyden
  • Patent number: 8808712
    Abstract: The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5??(1) (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: August 19, 2014
    Assignee: Osaka University
    Inventors: Toshihiro Horii, Ken Ishii, Takahiro Tougan
  • Patent number: 8809494
    Abstract: Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided. In addition methods for identifying agents which inhibit the function of these proteins as chemotherapeutic and/or immunologic agents for treatment and prevention of malaria infections are provided. Compositions for treatment and prevention of malaria infections and methods for preventing and treating malaria infections are also provided.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: August 19, 2014
    Assignee: Drexel University
    Inventors: Lawrence W. Bergman, Akhil B. Vaidya
  • Patent number: 8765147
    Abstract: The present disclosure relates to endophytic fungi from higher plants such as a Pteromischum sp. plant, and to extracts and compounds from such fungi that have desirable biological activities, such as antifungal and immunosuppressive activities. The present disclosure further relates to compositions comprising such extracts and compounds, as well as methods of making and using the compositions.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 1, 2014
    Assignee: The Regents of the University of California
    Inventors: Gary A. Strobel, Yuhao Ren, David B. Teplow
  • Patent number: 8481334
    Abstract: The invention features a method of attaching a ligand that has a free carboxyl group to a solid support by adding an amino group to the ligand to form a ligand-amino derivative, converting the ligand amino derivative to a ligand sulfhydryl derivative, attaching the ligand sulfhydryl derivative to a protein to form a ligand-linker-protein conjugate, and applying the ligand-linker-protein conjugate to the solid support. The method is particularly useful for immobilizing small molecule ligands having a free carboxyl group, such as cloxicillin, to a lateral-flow test strip, in order to make a detection zone on the test strip that exhibits a clear signal and enhanced sensitivity.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: July 9, 2013
    Assignee: Charm Sciences, Inc.
    Inventor: Steven J. Saul
  • Patent number: 8080256
    Abstract: The present disclosure relates to endophytic fungi from higher plants such as a Pteromischum sp. plant, and to extracts and compounds from such fungi that have desirable biological activities, such as antifungal and immunosuppressive activities. The present disclosure further relates to compositions comprising such extracts and compounds, as well as methods of making and using the compositions.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: December 20, 2011
    Assignee: Regents of the University of California
    Inventors: Gary A. Strobel, Yuhao Ren, David B. Teplow
  • Patent number: 7754224
    Abstract: Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: July 13, 2010
    Assignee: Research Development Foundation
    Inventors: Jere W. McBride, David H. Walker
  • Patent number: 7700120
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: April 20, 2010
    Assignee: New York Blood Center
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 7550426
    Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group, and an acetyl group. These agents are useful in treating cancer, especially prostate cancer.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: June 23, 2009
    Assignee: GHC Research Development Corporation
    Inventors: Thomas E. Wagner, Xianzhong Yu
  • Patent number: 7456146
    Abstract: A cytotoxin can be rendered non-toxic by charge neutralizing the amino acids salient to pore assembly and/or sterically inhibiting formation of the peptide's active conformation. In the presence of specific proteases, the inactive peptide or procytotoxin can be activated to assemble into its lytic conformation and selectively destroy a target cell.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: November 25, 2008
    Assignee: GHC Research Development Corporation
    Inventors: Xianxhang Yu, Thomas E. Wagner
  • Patent number: 7438917
    Abstract: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: October 21, 2008
    Assignee: Institut Pasteur
    Inventors: Claudine Guerin-Marchand, Pierre Druilhe
  • Patent number: 7425535
    Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in treating cancer, especially prostate cancer.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: September 16, 2008
    Assignee: GHC Research Development Corporation
    Inventors: Xianzhong Yu, Thomas E. Wagner
  • Patent number: 7419807
    Abstract: A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 2, 2008
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: W. James Jackson, John L. Pace
  • Patent number: 7351570
    Abstract: The invention concerns nucleic acid molecules derived from novel hepatitis D virus strains or isolates constituting genotypes different from known I, II and III genotypes, their fragments, corresponding proteins and their uses as diagnostic reagents. The invention also concerns a method for sensitive diagnosis of the hepatitis D virus (or delta hepatitis virus) and a method for epidemiologic monitoring of HDV-related infections.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: April 1, 2008
    Assignee: Assistance Publique-Hopitaux de Paris
    Inventors: Paul Deny, Nadjia Radjef, Patricia Huc-Anais
  • Patent number: 7335370
    Abstract: The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of Chlamydia pneumoniae. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: February 26, 2008
    Assignee: Aventis Pasteur Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
  • Patent number: 7326545
    Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: February 5, 2008
    Assignee: Sanofi Pasteur Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
  • Patent number: 7223836
    Abstract: Peptides are disclosed that include SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, or a conservative variant or mimic thereof, wherein the conservative variant or mimic specifically binds an antibody that specifically binds SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID or NO:6. These peptides are of use in generating an immune response against C. pneumoniae, or in preventing infection with against C. pneumoniae.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: May 29, 2007
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Eric L. Marston, Jackie S. Sampson, George M. Carlone, Edwin W. Ades
  • Patent number: 7211647
    Abstract: The object of the invention is to provide proteins that have both DNA primase activity and DNA polymerase activity. This subject is solved by a protein (p41) that has an amino acid sequence shown in SEQ ID NO: 1. This is for the first time that proteins that have both DNA primase activity and DNA polymerase activity were found. A protein (p46) that has amino acid sequence shown in SEQ ID NO: 2 forms a complex with p41, and enforces DNA synthesis activity that is independent and/or dependent from primer of p41.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: May 1, 2007
    Assignee: Celestar Lexico-Sciences, Inc.
    Inventors: Yoshizumi Ishino, Isaac Cann, Arnaud Bocquier, Lidong Liu
  • Patent number: 7204992
    Abstract: Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: April 17, 2007
    Assignee: Clayton Foundation for Research
    Inventors: Jere W. McBride, David H. Walker
  • Patent number: 7176178
    Abstract: A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: February 13, 2007
    Assignee: Hansa Medical AB
    Inventors: Lars Henrik Bjorck, Inga-Maria Frick, Tomas Borje Leandersson, Eugen J. K. Axcrona
  • Patent number: 7094750
    Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in treating cancer, especially prostate cancer.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: August 22, 2006
    Assignee: Greenville Hospital System
    Inventors: Xianxhang Yu, Thomas E. Wagner
  • Patent number: 7087231
    Abstract: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: August 8, 2006
    Assignee: Institut Pasteur
    Inventors: Claudine Guerin-Marchand, Pierre Druilhe
  • Patent number: 7074894
    Abstract: An isolated antigen against a Mycoplasma, prepared by a method including providing a sample of a Mycoplasma and an antibody probe, probing the Mycoplasma sample with the antibody probe to detect at least one antigen, and isolating the antigen detected. The antibody probe includes at least one antibody against the Mycoplasma that is produced by a method including (a) providing a biological sample taken a short time after an immune animal has been challenged with a Mycoplasma or Mycoplasma extract taken from the infection site or an area of a lesion or an area close to the infection site or lesion; (b) isolating cells from the biological sample; (c) culturing the cells in vitro in a suitable culture medium; and (d) harvesting antibodies produced from the cell.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: July 11, 2006
    Assignee: The University of Melbourne
    Inventors: John Walker, Rogan Lee, Stephen William Doughty
  • Patent number: 7067247
    Abstract: We isolated and characterized a new surface mutant of the hepatitis B virus surface antigen (HBsAg). The mutant was isolated from a symptomatic patient with Down's syndrome who was found to be persistently positive for both for HBsAg and anti-HBs Antibody (Ab) with an equally long-lasting anti-HB core (c) IgM Ab.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: June 27, 2006
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventor: Jian Zheng
  • Patent number: 6822071
    Abstract: Chlamydia pneumoniae polypeptides are provided. The C. pneumoniae polypeptides can be used to prepare pharmaceutical compositions for the treatment or prevention of disease. In addition, the proteins can be used in methods for the diagnosis of C. pneumoniae infection.
    Type: Grant
    Filed: November 11, 1999
    Date of Patent: November 23, 2004
    Assignee: The Regents of the University of California
    Inventors: Richard S. Stephens, Wayne Mitchell, Sue S. Kalman, Ronald Davis
  • Patent number: 6818409
    Abstract: A method for separating and purifying HA-positive progenitor toxin(s) (LL and/or L toxins) and HA-negative progenitor toxin (M toxin) from a Clostridium botulinum strain is provided. The method comprises applying a liquid containing both the HA-positive progenitor toxin(s) and the HA-negative progenitor toxin to a lactose column. Also provided is a method for separating and purifying neurotoxin (7S toxin) from HA-positive progenitor toxins, which comprises treating HA-positive progenitor toxins with an alkaline buffer and then applying the resulting liquid containing dissociated neurotoxin and non-toxic components to a lactose column. Activated pure HA-positive toxins (L and LL toxins) and neurotoxin are obtained by simple procedures.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: November 16, 2004
    Assignees: Eisai Company Ltd., Keiji Oguma
    Inventor: Kenji Oguma
  • Patent number: 6783930
    Abstract: A method for identifying suitable targets for antibacterial agents based on identifying targets of bacteriophage-encoded proteins is described. Also described are compositions useful in the identification methods and in inhibiting bacterial growth, and methods for preparing and using such compositions.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: August 31, 2004
    Inventors: Jerry Pelletier, Philippe Gros, Michael DuBow
  • Patent number: 6770281
    Abstract: The invention is directed to a peptide, comprising the amino acid sequence substantially as denoted by SEQ ID NO:1 and biologically functional homologues and derivatives thereof.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: August 3, 2004
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventors: Yaakov Naparstek, Rina Ulmansky, Yechezkel Kashi
  • Patent number: 6759516
    Abstract: The present invention relates to method of identifying gene sequences of potential vaccine antigens. Also included are gene sequences and the polypeptides encoded by the gene sequences as well as the use of such sequences to induce a protective immune response in animals. Particularly, the invention relates to identifying potential antigen gene sequences of Mycoplasma, preferably Mycoplasma hyopneumoniae. In one aspect of the present invention there is provided a method of identifying expression proteins translated from a nucleotide sequence in an expression vector, said method comprising the use of a marker co-expressed with a protein translated from the nucleotide sequence. In a further aspect of the present invention there is provided a method of identifying a therapeutic antigenic gene sequence encoding a therapeutic antigenic protein of a disease, from a sample of nucleotide sequences. Preferably the marker is a polyHis tag.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: July 6, 2004
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Robert John Moore, Timothy James Doran
  • Patent number: 6747129
    Abstract: The present invention is directed to a protein isolated from S. aureus that is the target of RAP, called TRAP, which is characterized by a molecular weight of about 21 KDa, is capable of being phosphorylated by RAP, and comprises an amino acid sequence of SEQ ID NO:2. In addition, the present invention is directed towards an antibody immunoreactive with TRAP that is preferably a monoclonal antibody or a humanized antibody but may be a polyclonal antibody. The invention provides a method of treating S. aureus infection by administering such a TRAP-inhibiting agent. The invention also features methods for identifying compounds that inhibit TRAP activity and/or inhibit TRAP-RAP interaction.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: June 8, 2004
    Assignee: The Regents of the University of California
    Inventors: Naomi Balaban, Tzipora Goldkorn
  • Patent number: 6689595
    Abstract: An unliganded form of Staphylococcus aureus thymidylate kinase (S. aureus TMK) has been crystallized, and the three dimensional x-ray crystal structure has been solved to 2.3 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S. aureus TMK activity.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: February 10, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventor: Timothy E. Benson
  • Patent number: 6638515
    Abstract: The present invention is directed to a method of blocking the cytotoxic activity of Fc&ggr;RIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using protein V specific for IgG1 and/or IgG3. In one aspect of the invention, protein V blocks the binding of IgG1 and/or IgG3 to the Fc&ggr;RIII receptor, which inactivates the receptor, and destroys cellular forms containing the receptor.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: October 28, 2003
    Inventor: Walter Schubert
  • Patent number: 6605280
    Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: August 12, 2003
    Assignee: Yeda Research and Development Company Limited
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim
  • Patent number: 6548070
    Abstract: Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: April 15, 2003
    Assignee: Aventis Pasteur Limited
    Inventors: Bruno Flesselles, Michel H. Klein
  • Patent number: 6485928
    Abstract: The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.
    Type: Grant
    Filed: November 3, 1998
    Date of Patent: November 26, 2002
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California
    Inventors: Steffen Stenger, Robert L. Modlin, Dennis Alan Hanson, Alan M. Krensky
  • Patent number: 6471966
    Abstract: Fimbriae adhesins have a molecular weight of 2×105 and 2×107 Da, and are comprised of 90-95% protein and 1-3% sugar. Type 1 fimbriae include five different protein fractions of 14-20 kDa, most of which are associated with carbohydrates. Type P fimbriae also include five different protein fractions of 14-20 kDa, and one of the majority proteins is associated with carbohydrates. The process of the invention comprises: culturing E. coli strains CECT 4484 and CECT 4485; collecting the sediment by centrifugation and resuspending it in physiological saline followed by homogenization; centrifuging the homogenate and collecting the supernatant; precipitating the supernatant with saline, reconstituting the precipitate and dialyzing the solution; treating the dialyzate with sodium deoxycholate and, subjecting the product to two successive chromatographies with Sephacryl S-200 and Sepharose 4B. The product is used for treatment and prevention of infections of the urinary tract caused by fimbriated E. coli.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: October 29, 2002
    Assignee: Industrial Farmaceutica y de Especialidades, S.A.
    Inventors: Ricardo Palacios Pelaez, Alberto Martinez Garate, Jorge Martinez Quesada
  • Patent number: 6444208
    Abstract: The invention provides rnc polypeptides and DNA (RNA) encoding rnc polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing rnc polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: September 3, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael Arthur Lonetto, Martin Rosenberg
  • Patent number: 6440423
    Abstract: Methods and compositions are provided herein for the se of a novel mutant form of E. coli heat-labile enterotoxin which has lost its toxicity but has retained its immunologic activity. This enterotoxin is used in combination with an unrelated antigen to achieve an increased immune response to said antigen when administered as part of an oral vaccine preparation.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: August 27, 2002
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: John D. Clements, Bonny L. Dickinson
  • Patent number: 6403094
    Abstract: The present invention provides proteins for use in vaccines which are capable of inducing protective antibodies directed against C. perfringens epsilon toxin when administered to animals or man and thereby providing prophylaxis or therapy against infection by C. perfringens epsilon toxin. Particularly the present invention provides proteins which are based upon the mature toxin of the clostridium perfringensepsilon toxin gene, but which have a mutation such that the amino acid at position 106 is different to the wild-type sequence and their use in vaccine compositions.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: June 11, 2002
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland
    Inventors: Richard W Titball, Ethel D Williamson, Helen L Havard, Petra C F Oyston, Dean W Payne
  • Patent number: 6403362
    Abstract: An expressing system which enables a large amount of production of a protein in Humicola, in particular, Humicola insolens, and particularly host-vector systems and a process for producing a protein using the systems, wherein an expression vector comprising the regulator sequences, i.e., the promoter, the signal sequence, and the terminator, of the cellulase NCE1 gene or NCE2 gene derived from Humicola insolens is constructed and used. The expression vector enables highly efficient production of cellulase NCE4, for example, in Humicola insolens at a rate as high as about 4.5 g or more per one liter of culture.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: June 11, 2002
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Tatsuki Moriya, Kouichirou Murashima, Kaoru Aoyagi, Naomi Sumida, Manabu Watanabe, Toru Hamaya, Jinichiro Koga, Toshiaki Kono, Takeshi Murakami
  • Patent number: 6346608
    Abstract: The invention provides mecB polypeptides and polynucleotides encoding mecB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing mecB polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: February 12, 2002
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham, PLC
    Inventors: Martin Karl Russel Burnham, Andrew Fosberry, John Hodgson, Deborah Jaworski, Elizabeth Lawlor, Martin Rosenberg, Lisa Kathleen Shilling, Min Wang, Judith Ward
  • Patent number: 6309648
    Abstract: The subject of the invention is amino acid sequences of the AC-Hly from B. pertussis. B. parapertussis and/or B. bronchiseptica, carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of the invention is antibodies, especially monoclonal antibodies, directed against these epitopes.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: October 30, 2001
    Assignee: Institut Pasteur
    Inventors: Fotini Betsou, Peter Sebo, Nicole Guiso
  • Gcp
    Patent number: 6274719
    Abstract: The invention provides gcp polypeptides and polynucleotides encoding gcp polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gcp polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: August 14, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Sanjoy Biswas, Alison Frances Chalker, David Holmes, Karen A Ingraham, Leslie Marie Palmer, Jennifer E Ray, Richard Lloyd Warren, Magdalena Zalacain
  • Patent number: 6258936
    Abstract: The invention provides spoIIIE polypeptides and DNA (RNA) encoding spoIIIE polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing spoIIIE polypeptide for the protection against infection, particularly bacterial infections.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: July 10, 2001
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John Edward Hodgson, Alison Frances Chalker
  • Patent number: 6255080
    Abstract: Proteinaceous antibiotics produced by ruminal bacteria are provided. The diverse group of ruminal bacteria known as Butyrivibrio spp. is a preferred source of such proteinaceous antibiotics. The proteinaceous antibiotics are generally resistant to gastric proteases, exhibit a high level of hydrophobicity, are effective to inhibit growth of target organisms under anaerobic conditions, are ineffective in aerobic conditions, and have a molecular weight of less than about 5 kDa. Also provided are methods for identifying ruminal bacteria which produce such proteinaceous antibiotics, and methods for producing the proteinaceous antibiotics.
    Type: Grant
    Filed: January 5, 1998
    Date of Patent: July 3, 2001
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Agriculture and Agri-Food
    Inventors: Ronald M. Teather, Robert J. Forster, Martin Kalmokoff
  • Patent number: 6248331
    Abstract: A Treponema pallidum fused antigen in which at least two surface antigens of Treponema pallidum are fused and an assay for anti-Treponema pallidum antibodies, using the above Treponema pallidum fused antigen.
    Type: Grant
    Filed: December 26, 1996
    Date of Patent: June 19, 2001
    Assignee: Fujirebio, Inc.
    Inventors: Nobuyuki Ise, Takeya Hori, Katsuya Fujimura, Tetsuji Tanimoto, Masahisa Okada
  • Patent number: 6222014
    Abstract: The invention provides nrdE polypeptides and polynucleotides encoding nrdE polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing nrdE polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: April 24, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael Terence Black, Christopher M Traini, Edwina Imogen Wilding
  • Patent number: 6171805
    Abstract: A DNA encoding a cell surface polypeptide of Porphyromonas gingivalis, and a recombinant DNA being a DNA having integrated said DNA thereinto. The cell surface polypeptide of the periodontopathic organism useful for prophylaxis and diagnosis of periodontal diseases can be obtained in a large amount by a microorganism containing the recombinant DNA wherein the DNA was integrated.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: January 9, 2001
    Assignees: Kyowa Hakko Kogyo Co., Ltd., Kyowa Medex Co., Ltd,, Meito Sangyo Kabushiki Kaisha
    Inventors: Hideharu Mori, Mamoru Hasegawa, Masanori Fukui, Kenji Yasuda, Keiko Yamada, Shusaburo Hokukoku, Tomohiko Ogawa
  • Patent number: 6171834
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murI of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurI enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: January 9, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Franklin Harpold Norris, Pamela Kay Rockey, Paul Robert Rosteck, Jr., Paul Luther Skatrud, Patti Jean Treadway, Michele Louise Young Bellido, Chyun-Yeh Earnest Wu